Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation.

about

Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation.

Item

http://www.wikidata.org/entity/Q52579907

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Review of targeted therapy in ...... know about CT interpretation.

@en

Review of targeted therapy in ...... know about CT interpretation.

@nl

type

Item

label

Review of targeted therapy in ...... know about CT interpretation.

@en

Review of targeted therapy in ...... know about CT interpretation.

@nl

prefLabel

Review of targeted therapy in ...... know about CT interpretation.

@en

Review of targeted therapy in ...... know about CT interpretation.

@nl

P1476

Review of targeted therapy in ...... o know about CT interpretation

@en

P2093

Angela Giardino

http://www.w3.org/2001/XMLSchema#string

Bhanusupriya Somarouthu

http://www.w3.org/2001/XMLSchema#string

Katherine Krajewski

http://www.w3.org/2001/XMLSchema#string

Matthew Davids

http://www.w3.org/2001/XMLSchema#string

Nikhil Ramaiya

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Rituximab: mechanism of action

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Genomic aberrations and survival in chronic lymphocytic leukemia

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Alemtuzumab in chronic lymphocytic leukemia

Clinical staging of chronic lymphocytic leukemia.

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

P2888

s40644-018-0146-8

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S40644-018-0146-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Francesco Alessandrino

Babina Gosangi

P5008

ScienceSource

P577

2018-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1103465723

http://www.w3.org/2001/XMLSchema#string

P698

29669600

http://www.w3.org/2001/XMLSchema#string

P921

chronic lymphocytic leukemia

P932

5907417

http://www.w3.org/2001/XMLSchema#string